2EB0

QUOIN PHARMACEUT.ADR5000

Healthcare · EUR · F

2EB0

Price

€3.789

-5.75%

Cap

€7.63M

Earnings

30d Trend

-19.8%

2EB0
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

81% annualised over 90 days

BRAIN47 SIGNAL

0
VERY WEAK
Risk Level85
Quality35
Momentum11
Technical36
Fundamentals50

Raw weighted: 25×Macro 0.99 (1%)=25

RISK

85/100
90d Volatility
81.3%High
ATR %
5.8%High daily moves
Max Drawdown (1Y)
-82.7%Volatile

QUALITY

35/100
Piotroski F-Score
2/9Weak
Accruals
-11.1%Cash earnings

MOMENTUM

11/100
12-1M Momentum
-41.3%Strong downtrend
6-1M Momentum
-67.5%Negative
1M Return
-11.4%Sharp decline

TECHNICAL

36/100
RSI (14)
29.5Oversold
Price vs SMA200
-52.5%Bearish trend
MACD
-0.07Bearish momentum
Bollinger Band
-3%Near lower band
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.231Noisy/choppy

FUNDAMENTALS

50/100

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months61
3-12 months20
1-5+ years34

5-10 day swing — oversold bounce candidate

BRAIN47'S ASSESSMENT

I rate QUOIN PHARMACEUT.ADR5000 at 25/100 — a VERY WEAK reading on the Brain47 Signal. The strongest factor is fundamentals at 50/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-11.4%

3 MONTHS

-44.0%

12 MONTHS

-52.7%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

5-10 day swing — oversold bounce candidate. Fundamentals (50) and Technical (36) are the primary strengths. I note that momentum is the weakest area at 11/100 — this warrants monitoring. Historical volatility is elevated at 81%. I classify this as a speculative position — elevated volatility at 81% and smaller market cap define the opportunity.

speculativeScore: 25/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.